For Your Information
FTC Approves Final Order Preserving Competition in Market for BRAF- and MEK-Inhibitor Oncology Drugs
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG’s $16 billion acquisition of GlaxoSmithKline’s portfolio of cancer-treatment drugs likely would be anticompetitive.
Under the order, first announced in February 2015, Novartis has agreed to divest all assets related to its BRAF- and MEK-inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma.
The Commission vote approving the final order was 5-0. (FTC File 141-0141; the staff contact is Stephanie Bovee, Bureau of Competition, 202-326-2083)
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Press Release Reference
Contact Information
MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707